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Abstract
Background: Proton pump inhibitors (PPI) have reportedly 
been used in inappropriate clinical settings, often leading to 
an increased risk of adverse effects, drug interactions, and 
costs. Aim: The aim of this study was to evaluate the adequa-
cy of PPI prescription in an internal medicine ward. Methods: 
The discharged home inpatients of a segment in the medi-
cine department of a central hospital in the first trimester of 
2017 were evaluated; those who died or were transferred to 
another unit were excluded. Data on gender, age, admission, 
and discharge therapy and diagnoses which could support 
PPI use were collected from clinical records. Statistical analy-
sis was performed using Microsoft Excel 2013® and IBM SPSS 
Statistics 20®. Results: A total of 318 hospitalizations were 
included, corresponding to 301 patients; 171 (56.8%) were 
female and the average age was 75.4 ± 14.6 years. Among 
the 318 hospitalizations, 148 patients (46.5%) were on PPI at 
admission and 175 (55%) at discharge, the majority of them 
without indication (n = 91, 61.5% vs. n = 109, 62.3%). The 
main inappropriate indication was anticoagulation alone 
(n = 33, 36.3% vs. n = 43, 39.4%). There was indication for PPI 
therapy in 93 (29.2%) of the cases at admission and 111 
(34.9%) at discharge, mostly for prophylaxis of gastrointesti-
nal bleeding in high-risk patients (n = 82, 88.2% vs. n = 96, 
86.5%). Among those with indication, 57 (61.3%) were med-
icated at admission versus 66 (59%) at discharge. The asso-
ciation between PPI therapy and an indication for its pre-
scription was lost by the time of discharge (p = 0.245). Con-
clusions: PPI prescription is not in agreement with existing 
recommendations, which is why it should be revised at hos-
pital discharge. The primary indication for PPI therapy is the 
prophylaxis of gastrointestinal bleeding in high-risk patients 
and the main inappropriate indication is prophylaxis in low-
risk patients. A large proportion of the patients indicated for 
PPI use were discharged without prescription.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
Introdução: Os inibidores da bomba de protões (IBP) têm 
sido utilizados em situações sem indicação, com aumento 
do risco de efeitos adversos, interações medicamentosas 
e custos. Objetivo: Avaliar a pertinência da prescrição dos 
IBP numa enfermaria de Medicina Interna. Métodos: 
Foram avaliados os internamentos de uma Enfermaria de 
Medicina de um Hospital Central, cuja alta ocorreu para o 
domicílio no 1° trimestre de 2017; foram excluídos aqueles 
que morreram ou foram transferidos. Foram recolhidos os 
seguintes dados do processo clínico: género, idade, ter-
apêutica à admissão e à alta; antecedentes pessoais ou 
diagnósticos que pudessem sustentar a toma de IBP. A 
análise estatística foi realizada através do Microsoft Excel 
2013® e IBM SPSS Statistics 20®. Resultados: Foram in-
cluídos 318 internamentos, correspondentes a 301 doen-
tes, 171 (56.8%) do género feminino, com uma idade mé-
dia de 75.4 ± 14.6 anos. Nos 318 internamentos, 148 doen-
tes (46.5%) estavam sob IBP à admissão e 175 (55%) à alta, 
a maioria (n = 91, 61.5% vs. n = 109, 62.3%) sem indicação. 
A principal indicação inapropriada foi a anticoagulação 
isolada (n = 33, 36.3% vs. n = 43, 39.4%). Houve indicação 
para uso de IBP em 93 (29.2%) casos à admissão e 111 
(34.9%) à alta, na maioria (n = 82, 88,2% vs. n = 96, 86.5%) 
para profilaxia de hemorragia gastrointestinal em doen-
tes de alto risco. Dos doentes com indicação, apenas 57 
(61.3%) estavam medicados à admissão versus 66 (59%) à 
alta. Houve uma perda de associação entre a terapêutica 
com IBP e a existência de indicação para a sua prescrição 
no momento da alta (p = 0.245). Conclusões: A prescrição 
de IBP é incongruente com as recomendações, pelo que 
esta deve ser revista no momento da alta. A principal in-
dicação para IBP é a profilaxia de hemorragia gastrointes-
tinal em doentes de alto risco e a principal indicação ina-
propriada é a sua profilaxia em doentes de baixo risco. 
Uma proporção significativa de doentes com indicação 
para IBP teve alta sem a sua prescrição.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Omeprazole was the first proton pump inhibitor (PPI) 
discovered and has been available in Europe for acid sup-
pression since 1988. Subsequently, other drugs have been 
identified and several alternatives are currently available: 
lansoprazole, pantoprazole, rabeprazole, dexlansopra-
zole, and esomeprazole [1].
Compared with histamine-2 receptor antagonists, 
these drugs are more powerful in decreasing gastric acid-
ity, which has revolutionized the treatment of peptic ulcer 
disease and gastroesophageal reflux disease (GERD). PPI 
have also assumed a leading role in the eradication of He-
licobacter pylori, pathological hypersecretion (such as 
Zollinger-Ellison syndrome), and prophylaxis of gastro-
intestinal bleeding in high-risk patients. 
However, supported by its excellent effectiveness and 
safety profile, there has been an expansion of its use in 
inappropriate clinical contexts, such as the prophylaxis of 
gastrointestinal bleeding in low-risk patients and usage 
for longer than indicated. This increased prescription of 
PPI, allied to its growing accessibility due to the emer-
gence of generics and over-the-counter availability, plac-
es PPI amongst the most selling drugs in the world. 
However, its use is not innocuous and several studies 
document potential adverse effects such as acute intersti-
tial nephritis, gastric polyposis, vitamin B12 and magne-
sium deficiency, Clostridium difficile infection or bacte-
rial overgrowth in cirrhotic patients with an increased 
risk of spontaneous bacterial peritonitis [2, 3]. Addition-
al studies are still needed to clarify the relationship be-
tween the use of PPI and certain adverse effects and, 
therefore, its prescription should not be discouraged 
when indicated [4]. It should also be noted that there has 
been an expansion of PPI prescription to all age groups, 
including polymedicated elderly, thus increasing the risk 
of drug interactions. Such overuse of PPI has a financial 
impact on patients and public health spendings alike.
Aim
The aim of this study was to evaluate the adequacy of 
PPI prescription in an internal medicine ward, compar-
ing its use at admission and discharge.
Methods
A list of patients discharged from the Functional Unit of Med-
icine 1.2 between January 1 and March 31, 2017 was obtained. The 
study included all the patients discharged home and excluded 
those who died or who were transferred to another hospital unit. 
Discharge letters were consulted to collect the following data: (1) 
age and gender; (2) pre-hospitalization and discharge medication 
(PPI, anti-platelet drugs, anticoagulants, corticosteroids, nonste-
roidal anti-inflammatory drugs [NSAIDs], and selective cyclooxy-
genase [COX-2] inhibitors); (3) personal history or recent diagno-
sis that supported the use of PPI. A history of peptic ulcer docu-
mented on upper digestive endoscopies was sought in the patient’s 
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electronic record. The indications considered valid are listed in 
Tables 1 and 2.
A χ2 test was used to evaluate the association between variables 
and it was considered statistically significant when p < 0.05. Statis-
tical analysis was performed using Microsoft Excel 2013® and IBM 
SPSS Statistics 20®.
Results
From January 1 to March 31, 2017, there were 384 dis-
charges from the Functional Unit of Medicine 1.2. Among 
those patients, 318 (82.8%) were discharged home, 50 
(13%) died, and 16 (4.2%) were transferred to another 
hospital unit. A total of 301 patients were included in the 
study, since 14 of them had more than 1 hospitalization 
within this period of time.
Demographically, 171 patients (56.8%) were female 
and 130 (43.2%) were male. The patients’ ages ranged 
from 19 to 102, with an average age of 75.4 ±14.6.
Of the 318 cases analyzed, 148 (46.5%) were on PPI 
therapy at admission, most of them under omeprazole 
(n = 66, 44.6%), followed by pantoprazole (n = 54, 36.5%); 
175 patients (55%) were discharged with a PPI prescrip-
tion, most of them with pantoprazole (n = 87, 49.7%), fol-
lowed by omeprazole (n = 56, 32%). Lansoprazole was 
preferred in 5 (3.4%) patients at admission and 3 (1.7%) 
at discharge. None of the patients included in this study 
had a rabeprazole prescription at admission or discharge. 
Esomeprazole had intermediate use rates (n = 23, 15.5% 
at admission vs. n = 29, 16.6% at discharge). 
Ninety one (61.5%) of the PPI users on admission had 
no indication for this therapy, according to the indica-
tions expressed in Tables 1 and 2. While analyzing these 
prescriptions we found several likely justifications for 
this, which are shown in Table 3.
On the other hand, of all 318 analyzed cases, 93 (29.2%) 
had an indication for PPI use on admission, most of them 
(n = 82, 88.2%) for gastrointestinal bleeding prophylaxis. 
The distribution of prophylactic indications for PPI use 
was as follows: 78 (95.1%) patients were older than 65 
years and were under concomitant antiplatelet therapy, 
Table 1. Indications for use of PPI according to the Food and Drug 
Administration (FDA) and the National Institute for Clinical Ex-
cellence (NICE) [5–13]
– Erosive esophagitis – healing and maintenance therapy
– GERD and its clinical manifestations (including nonerosive 
disease, symptomatic control*, esophageal strictures, Barrett’s 
esophagus)
– HP eradication in combination with antibiotics
– Short-term treatment of HP-negative peptic ulcers and main-
tenance therapy
– Treatment of gastric ulcers associated with NSAIDs
– NSAID-induced dyspepsia
– Reduction of risk of gastric ulcers in NSAID users with a high 
risk** of gastrointestinal complications or COX-2 inhibitor 
users with previous history of upper gastrointestinal bleeding
– Gastric pathological hypersecretion (Zollinger-Ellison dis-
ease)
– Critically ill patients, under prolonged mechanical ventilation
– Short-term treatment* of patients with functional dyspepsia
* 4–8 weeks of treatment, followed by minimum effective dose 
or use on demand, if symptoms persist. ** Age >65 years or con-
comitant use of corticosteroids, antiplatelet agents, or anticoagu-
lants or previous history of peptic ulcer disease.
Table 2. Other valid indications for PPI therapy [8, 12, 14, 15]
– Reduction of risk of gastric ulcers in high-risk patients* 
treated with antiplatelet agents
– Eosinophilic esophagitis
– Steatorrhea refractory to enzyme replacement therapy in 
patients with exocrine pancreatic insufficiency
– Prior to upper gastrointestinal endoscopy for upper gastro-
intestinal bleeding and following endoscopic therapy in pa-
tients with high-risk ulcers**
*  Age >65 years or concomitant use of corticosteroids or 
anticoagulants or previous history of peptic ulcer disease. ** Forrest 
classification Ia, Ib, IIa, and IIb.






Anticoagulation* 33 36.3% 43 39.4%
Corticotherapy* 9 9.9% 9 8.3%
Anticoagulation and corticotherapy* 9 8.3%
Gastritis 10 11% 8 7.3%
Previous history of ulcer* 5 5.5% 8 7.3%
Chronic hepatic disease 4 4.4% 6 5.5%
Antiplatelet monotherapy* 2 2.2% 5 4.6%
NSAID* 1 0.9%
No perceptible cause 28 30.8% 20 18.3%
* Without any concomitant risk factors to justify PPI use.
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12 of whom (14.6%) were also anticoagulated and 4 
(4.9%) had a previous history of ulcer; 1 patient (1.2%) 
was under simultaneous antiplatelet and corticosteroid 
therapy; 3 patients (3.7%) were both older than 65 and 
under NSAID therapy, 1 of whom (1.2%) had a previous 
history of ulcer. Eleven patients (11.8%) had indication 
for therapeutic PPI use: 9 of these (81.8%) due to GERD 
and 2 (18.2%) due to dyspeptic symptoms. The indica-
tions for PPI on admission are summarized in Table 4. 
Among the patients with valid indications for PPI use on 
admission, only 57 (61.3%) were under PPI therapy.
Regarding PPI users on discharge, 109 (62.3%) had no 
indication for this therapy as defined by the FDA and 
NICE, meaning that PPI use was indicated in only 66 
(37.7%) of the analyzed patients. The most plausible jus-
tifications for the use of PPI with no indication are de-
scribed in Table 3. 
Similarly, by analyzing all hospitalizations, we found 
that 111 patients (34.9%) had indication for PPI at dis-
charge, 96 of them (86.5%) with prophylactic intent. The 
distribution of prophylactic indications for PPI use at dis-
charge is summarized as follows: 95 patients (99%) were 
over 65 years old and were under antiplatelet therapy, 10 
(10.4%) of whom were also anticoagulated, 6 (6.3%) were 
concurrent corticosteroid users, and 4 (4.2%) had a previ-
ous history of ulcer; 1 patient (1%) was under concomitant 
antiplatelet and corticosteroid drugs (without age as a risk 
factor). Of the 15 patients (13.5%) with indication for ther-
apeutic PPI, 11 (73.3%) had GERD, 2 (13.3%) had dyspep-
tic symptoms, 1 (6.7%) was undergoing Helicobacter pylori 
eradication therapy for dyspeptic symptoms, and 1 (6.7%) 
was on ulcer therapy. Indications for PPI at discharge are 
summarized in Table 4. Among patients with indication 
for PPI at discharge, 66 (59%) were under PPI therapy.
Tables 5 and 6 show the distribution of patients ac-
cording to whether or not they were undergoing PPI, tak-
ing into account the existence of an indication for its pre-
scription, at admission and discharge.
Although there is a correlation between PPI therapy at 
admission and an indication for its prescription (χ2 (1) = 
11.493, p = 0.001), this is not carried on to discharge 
(χ2 (1) = 1,351, p = 0.245).
During hospitalization, PPI was suspended in 17 pa-
tients (5.3%), correctly in 13 cases (76.5%) but improp-
Table 4. Distribution of indications for PPI at admission and dis-
charge
Indication Admission Discharge
n %** n %**
Prophylaxis* 82 88.2% 96 86.5%
NSAIDs 3 3.7% 0 0.0%
Age >65 3 3.7% 0 0.0%
Previous history of ulcer 1 1.2% 0 0.0%
Antiplatelet drugs 79 96.3% 96 100.0%
Age >65 78 95.1% 95 99.0%
Corticosteroids 1 1.2% 7 7.3%
Anticoagulants 12 14.6% 10 10.4%
Previous history of ulcer 4 4.9% 4 4.2%
Therapeutic 11 11.8% 15 13.5%
GERD 9 81.8% 11 73.3%
Dyspeptic symptoms 2 18.2% 3 20.0%
Ulcer healing 0 0.0% 1 6.7%
HP eradication 0 0.0% 1 6.7%
Total 93 100.0% 111 100.0%
* Excluding patients with simultaneous indication for thera-
peutic PPI. ** Percentage of total patients indicated for prophylac-
tic or therapeutic PPI (each patient may be included in more than 
one subindication, as described in the text).
Table 5. Distribution of patients by use of PPI, according to indica-
tion for their prescription, at admission
PPI use at admission Total
no yes
PPI indication at admission
No 134 91 225
Yes 36 57 93
Total 170 148 318
Table 6. Distribution of patients by use of PPI, according to indi-
cation for their prescription, at discharge
PPI use at discharge Total
no yes
PPI indication at discharge
No 98 109 207
Yes 45 66 111
Total 143 175 318
Gamelas/Salvado/DiasGE Port J Gastroenterol 2019;26:114–120118
DOI: 10.1159/000488506
erly in 4 patients (23.5%) who had an indication for PPI 
on discharge due to antiplatelet therapy associated with 
other risk factors. On the other hand, PPI was introduced 
in 44 patients (13.8%), with no indication in most of them 
(n = 27, 61.4% vs. n = 17, 38.6%).
Discussion
This study included 301 patients who represented the 
population of an internal medicine ward, with a slight 
predominance of women (56.8%) and an average age of 
75. This sample only concerns a restricted period of time 
and a single hospital unit, which limits the extrapolation 
of data to other sites or longer periods of time. As a ret-
rospective analysis, data was obtained through records 
with possible errors or omissions of risk factors or thera-
peutic indications, which could have led to statistical bias.
Our analysis focuses on hospitalization episodes rath-
er than patients, who may have been considered more 
than once. In fact, PPI prescription indications are dy-
namic and should be evaluated periodically in order to 
adjust prescription accordingly. Supported by this, the 
authors found no significant difference between analyz-
ing two different patients or the same patient at different 
moments. 
The indications for PPI use considered in this analysis 
include both a group of well-accepted indications as well 
as others considered valid by experts but not yet covered 
by current recommendations. Even though other indica-
tions are emerging, scientific evidence is still lacking, and 
therefore, further research is required. Examples of such 
indications are: treatment or prevention of chemothera-
py-induced GERD and gastroduodenal ulceration in can-
cer patients; dual antiplatelet therapy or anticoagulation 
without other risk factors; use of selective serotonin reup-
take inhibitors; use of COX-2 inhibitors in high-risk pa-
tients due to other reasons than previous gastrointestinal 
bleeding; and patients on high doses of NSAID even with-
out other risk factors [13, 15].
Omeprazole and pantoprazole were shown to be the 
most prescribed PPI, and it seems there is a preference for 
pantoprazole at hospital discharge. On the other hand, 
lansoprazole and rabeprazole were rarely used. Neverthe-
less, it should be noted that rabeprazole and pantopra-
zole, due to their lower dependence on cytochrome 
CYP2C19 metabolism, may be preferable in an elderly 
and polymedicated population as it would decrease the 
likelihood of drug interactions.
Our analysis shows that nearly half of the patients 
(46.5% at admission and 55% at discharge) were under 
PPI therapy, which was not indicated in more than half 
of them (61.5% at admission and 62.3% at discharge). 
These results are in agreement with similar studies car-
ried out elsewhere [9, 16, 19]. Overprescription of PPI in 
this group of patients appears to be mainly due to ulcer 
prophylaxis in low-risk patients, especially in anticoagu-
lated patients (36.3 and 39.4% at admission and discharge, 
respectively) or patients undergoing corticosteroid ther-
apy (9.9% at admission and 16.5% at discharge). In con-
trast to antiplatelet drugs, anticoagulants do not affect 
gastric protection mechanisms and may only increase 
bleeding risk in patients with prior gastrointestinal inju-
ry. The use of PPI in anticoagulated patients without con-
comitant use of NSAIDs or antiplatelet agents is therefore 
not recommended. In the same way, unlike NSAIDs, 
whose association with gastric mucosal lesion is well 
known, corticosteroid gastrotoxicity is not well docu-
mented and is inconsistent among different studies [20–
23]. As a result, the use of PPI in the absence of NSAIDs 
and/or concomitant antiplatelet therapy is also not rec-
ommended. It should also be noted that there is recent 
evidence of an increased risk for hepatic encephalopathy 
in cirrhotic patients using PPI [24]. Such patients are of-
ten incorrectly prescribed PPI for gastritis or chronic liv-
er disease.
It was decided not to address patients’ anemia in the 
present study given its multiple etiologies and since it was 
not possible to establish an association between its pres-
ence and PPI prescription rationale. However, similar 
studies suggest anemia to be an important factor for inap-
propriate prescription of PPI [16].
It was observed that about one-third of patients (29.2% 
at admission and 34.9% at discharge) were eligible for PPI 
therapy. Among them, only 60% (61.3 and 59.5% at ad-
mission and discharge, respectively) were prescribed a 
PPI. This shows that, in addition to an expansion of PPI 
use into inappropriate clinical settings, there is also an 
undermedication of patients with well-established indi-
cations for PPI. The vast majority of these patients had 
indication for ulcer prophylaxis (88.2% at admission and 
86.5% at discharge), mainly due to advanced age and an-
tiplatelet therapy, in the context of a high prevalence of 
cardiovascular disease in an elder population.
It is worth mentioning that only a small number of pa-
tients in this study are reported to use NSAIDs therapy, 
although this has been reported in other studies as an im-
portant cause of PPI therapy [19]. In fact, in the elderly, 
where the prevalence of osteoarticular disease is high, its 
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use would be expected to be more prevalent than de-
scribed. This underestimation may be explained by the 
omission of this therapy, since it is taken on demand and/
or without the need for medical prescription.
The indication for therapeutic PPI was present in 
slightly more than one-tenth of patients (11.8% at admis-
sion and 13.5% at discharge), especially for GERD and 
dyspeptic symptoms. The dyspeptic symptomatology is 
also rarely mentioned in discharge letters and may justify 
some apparently unjustified PPI use. However, this is a 
short-term or on-demand indication and should not jus-
tify a long-term PPI use in the absence of other indica-
tions.
Nonetheless, possible omissions may reflect non-reas-
sessment of the indication to maintain PPI therapy at dis-
charge, which should be done routinely at this time (as 
with other pharmacological classes with poorer safety 
profiles). Hospitalization had little effect on the correc-
tion of prior outpatient prescription, which was demon-
strated by similar percentages of inadequate prescription 
of PPI or failure to prescribe a PPI in the presence of a 
valid indication at admission and discharge. It was ob-
served that it was more common to introduce PPI at dis-
charge rather than suspend them, even in the absence of 
an indication to support their prescription. Such decision 
often results in a loss of association between the existence 
of PPI indication and its prescription.
We therefore emphasize the importance of reviewing 
PPI therapy according to valid indications in order to re-
duce polymedication, drug interactions, or adverse ef-
fects, as well as associated costs.
We hypothesize that an upper endoscopic study could 
help stratify the risk of patients whose previous history of 
ulcer was unknown. This would help defining the risk-
benefit relation of antiplatelet/anticoagulant therapy and 
the need for PPI prophylaxis, since gastrointestinal bleed-
ing may aggravate cardiovascular pathology, turning an-
ticoagulants and antiplatelet drugs into aggravating fac-
tors for cardiovascular disease rather than preventive 
ones. 
In conclusion, the study showed no relation between 
the indications for the use of PPI and its effective pre-
scription. The primary indication for PPI therapy is the 
prophylaxis of gastrointestinal bleeding in high-risk pa-
tients, with a large proportion of these patients being dis-
charged without prescription. The main inappropriate 
indication is the prophylaxis of gastrointestinal bleeding 
in low-risk patients. Hospitalization has a reduced impact 
on correcting prescription errors. A correct evaluation of 
the individual risk and revision of the indication for PPI 
at discharge should therefore be a priority.
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